 Home > Active Ingredient News > Drugs Articles > Express $130 million to help develop an innovative drug discovery platform for undruggable targets

Express $130 million to help develop an innovative drug discovery platform for undruggable targets

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

all natural cosmetics

drug discovery process

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Belharra Therapeutics announced the completion of a $50 million Series A funding round and a move out of stealth mode
.
The company also announced a multi-year R&D collaboration with Roche's Genentech to discover non-covalent, small molecule drug candidates for oncology, autoimmune, and neurodegenerative diseases
using a photoaffinity-based chemical proteomics platform.
Under the agreement, Belharra receives an upfront payment of $80 million and milestone payments
of up to $2 billion.

Photoaffinity-based chemoproteomics platform to discover non-covalent, small molecule drug candidates for the treatment of oncology, autoimmune, and neurodegenerative diseases
.

Belharra's integrated chemical proteomics-based drug development engine overcomes the limitations of traditional high-throughput screening by exploring protein/ligand interactions in the cell's natural environment through a unique library of photoaffinity-based chemical probes
.
This platform immobilizes unique non-covalent protein/ligand interactions based on photoaffinity, combined with an innovative chemical proteomics platform and bioinformatics capabilities, to fully explore probe/protein interactions and discover innovative druggable pockets
.
This photoaffinity platform does not require unique amino acid labeling and is able to explore the entire proteome
.

This platform holds a unique non-covalent protein/ligand interaction in place based on photoaffinity, a photoaffinity platform that does not require labeling with unique amino acids and enables exploration of the entire proteome
.

Image source: Belharra Therapeutics official website

The company's next-generation chemical proteomics platform allows the screening process to take place in a whole-cell environment, allowing small molecule compound libraries to interact with proteins in their natural conformation, including protein complexes
.
It has the potential to
discover a new generation of therapies that were previously difficult to treat.

The next-generation chemoproteomics platform allows the screening process to take place in a cell-intact environment, allowing small compound libraries to interact with proteins in their natural conformation

"We have increased the power of traditional chemical proteomics screening strategies and integrated them into a drug discovery engine that enables comprehensive targeting of all protein types and targets
.
" Jeff , CEO of Belharra Mr.
Jonker said, "This platform allows us to quickly re-screen all previous 'drug-free' targets and discover druggable, non-covalent ligands combined with functional pockets
.
”

Original link: https://belharratx.
com/companynews/belharra-therapeutics-debuts-with-130-million-in-funding/

https://belharratx.
com/companynews/belharra-therapeutics-debuts-with-130-million-in-funding/

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.